Digestive Diseases and Sciences

, Volume 62, Issue 9, pp 2489–2497 | Cite as

Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis

  • Eun Soo Kim
  • Kyeong Ok Kim
  • Byung Ik Jang
  • Eun Young Kim
  • Yoo Jin Lee
  • Hyun Seok Lee
  • Seong Woo Jeon
  • Hyun Jin Kim
  • Sung Kook KimEmail author
  • On behalf of Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)
Original Article



Although colonoscopy preparation may cause symptom flares in patients with ulcerative colitis (UC), little is known about the standard preparation regimen in this population.


We aimed to compare 4L polyethylene glycol (4L-PEG) with 2L polyethylene glycol plus ascorbic acid (2L-PEG-Asc) in quiescent UC patients.


Patients with inactive UC undergoing colonoscopy for surveillance or checkup of mucosal healing were prospectively enrolled at 5 tertiary hospitals. They were randomly assigned to 4L-PEG and 2L-PEG-Asc groups. The Boston Bowel Preparation Scale (BBPS) was used for the preparation quality. Symptoms were assessed using the Simple Clinical Colitis Activity Index (SCCAI) before colonoscopy, at 1 and 4 weeks after the procedure.


Overall, 109 patients were included in the study (4L-PEG group 53, 2L-PEG-Asc group 56, the mean age at diagnosis 42.25 years, male 77). The quality of preparation was comparable between the groups (BBPS ≥ 6, 96.2 vs. 92.9%, p = 0.679). Although 26 patients (23.8%) had increased SCCAI scores within 4 weeks after colonoscopy, resulting in a medication dose-up or add-on in 3 patients (2.7%), the rise in scores was not different between the groups. No serious adverse events during preparation were observed in either group. However, the 2L-PEG-Asc group was more likely to be willing to repeat the preparation with the same agent than the 4L-PEG group (82.1 vs. 64.2%, respectively, p = 0.034).


PEG-based regimens with different volumes are equally effective and safe in inactive UC patients. 2L-PEG-Asc is more acceptable in this population as indicated by the willingness for further usage.


Ulcerative colitis Colonoscopy Preparation Polyethylene glycol 



This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1D1A1A02062168).

Compliance with ethical standards

Conflict of interest



  1. 1.
    Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.CrossRefPubMedGoogle Scholar
  2. 2.
    Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14:111–119.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786.CrossRefPubMedGoogle Scholar
  4. 4.
    Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–346.CrossRefPubMedGoogle Scholar
  5. 5.
    Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.CrossRefPubMedGoogle Scholar
  6. 6.
    Itzkowitz SH, Present DH, Crohn’s, et al. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.CrossRefPubMedGoogle Scholar
  7. 7.
    Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.CrossRefPubMedGoogle Scholar
  8. 8.
    Mescoli C, Albertoni L, D’Inca R, et al. Dysplasia in inflammatory bowel diseases. Dig Liver Dis. 2013;45:186–194.CrossRefPubMedGoogle Scholar
  9. 9.
    Siddiqui AA, Yang K, Spechler SJ, et al. Duration of the interval between the completion of bowel preparation and the start of colonoscopy predicts bowel-preparation quality. Gastrointest Endosc. 2009;69:700–706.CrossRefPubMedGoogle Scholar
  10. 10.
    Denters MJ, Schreuder M, Depla AC, et al. Patients’ perception of colonoscopy: patients with inflammatory bowel disease and irritable bowel syndrome experience the largest burden. Eur J Gastroenterol Hepatol. 2013;25:964–972.CrossRefPubMedGoogle Scholar
  11. 11.
    Friedman S, Cheifetz AS, Farraye FA, et al. Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:534–539.CrossRefPubMedGoogle Scholar
  12. 12.
    Committee ASoP, Saltzman JR, Cash BD, et al. Bowel preparation before colonoscopy. Gastrointest Endosc 2015;81:781–794.Google Scholar
  13. 13.
    Present DH. Toxic megacolon. Med Clin North Am. 1993;77:1129–1148.CrossRefPubMedGoogle Scholar
  14. 14.
    Menees S, Higgins P, Korsnes S, et al. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12–18.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim ES, Cho KB, Park KS, et al. Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol. 2013;47:e38–e44.CrossRefPubMedGoogle Scholar
  16. 16.
    Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Park SS, Sinn DH, Kim YH, et al. Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning colonoscopy. Am J Gastroenterol. 2010;105:1319–1326.CrossRefPubMedGoogle Scholar
  18. 18.
    Lai EJ, Calderwood AH, Doros G, et al. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69:620–625.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jowett SL, Seal CJ, Phillips E, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38:164–171.CrossRefPubMedGoogle Scholar
  20. 20.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRefPubMedGoogle Scholar
  21. 21.
    Kao D, Lalor E, Sandha G, et al. A randomized controlled trial of four precolonoscopy bowel cleansing regimens. Can J Gastroenterol. 2011;25:657–662.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Manes G, Fontana P, de Nucci G, et al. Colon cleansing for colonoscopy in patients with ulcerative colitis: efficacy and acceptability of a 2-L PEG plus bisacodyl versus 4-L PEG. Inflamm Bowel Dis. 2015;21:2137–2144.CrossRefPubMedGoogle Scholar
  23. 23.
    Xie Q, Chen L, Zhao F, et al. A meta-analysis of randomized controlled trials of low-volume polyethylene glycol plus ascorbic acid versus standard-volume polyethylene glycol solution as bowel preparations for colonoscopy. PLoS One. 2014;9:e99092.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Repici A, Cestari R, Annese V, et al. Randomised clinical trial: low-volume bowel preparation for colonoscopy—a comparison between two different PEG-based formulations. Aliment Pharmacol Ther. 2012;36:717–724.CrossRefPubMedGoogle Scholar
  25. 25.
    Schwesinger WH, Levine BA, Ramos R. Complications in colonoscopy. Surg Gynecol Obstet. 1979;148:270–281.PubMedGoogle Scholar
  26. 26.
    Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointest Endosc. 1977;23:150–154.CrossRefPubMedGoogle Scholar
  27. 27.
    Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.CrossRefPubMedGoogle Scholar
  28. 28.
    Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–194; author reply 195.Google Scholar
  29. 29.
    Watts DA, Lessells AM, Penman ID, et al. Endoscopic and histologic features of sodium phosphate bowel preparation-induced colonic ulceration: case report and review. Gastrointest Endosc. 2002;55:584–587.CrossRefPubMedGoogle Scholar
  30. 30.
    Atkinson RJ, Save V, Hunter JO. Colonic ulceration after sodium phosphate bowel preparation. Am J Gastroenterol. 2005;100:2603–2605.CrossRefPubMedGoogle Scholar
  31. 31.
    Coskun A, Uzunkoy A, Duzgun SA, et al. Experimental sodium phosphate and polyethylene glycol induce colonic tissue damage and oxidative stress. Br J Surg. 2001;88:85–89.CrossRefPubMedGoogle Scholar
  32. 32.
    Vila V, Brullet E, Montserrat A, et al. Glutaraldehyde-induced iatrogenic rectocolitis. Gastroenterol Hepatol. 2001;24:409–410.CrossRefPubMedGoogle Scholar
  33. 33.
    Hanson JM, Plusa SM, Bennett MK, et al. Glutaraldehyde as a possible cause of diarrhoea after sigmoidoscopy. Br J Surg. 1998;85:1385–1387.CrossRefPubMedGoogle Scholar
  34. 34.
    Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc. 1996;43:42–48.CrossRefPubMedGoogle Scholar
  35. 35.
    Caprilli R, Vernia P, Colaneri O, et al. Risk factors in toxic megacolon. Dig Dis Sci. 1980;25:817–822.CrossRefPubMedGoogle Scholar
  36. 36.
    Driman DK, Preiksaitis HG. Colorectal inflammation and increased cell proliferation associated with oral sodium phosphate bowel preparation solution. Hum Pathol. 1998;29:972–978.CrossRefPubMedGoogle Scholar
  37. 37.
    Hixson LJ. Colorectal ulcers associated with sodium phosphate catharsis. Gastrointest Endosc. 1995;42:101–102.CrossRefPubMedGoogle Scholar
  38. 38.
    Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634–1640.CrossRefPubMedGoogle Scholar
  39. 39.
    Rosenberg L, Lawlor GO, Zenlea T, et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013;19:779–784.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Pontone S, Angelini R, Standoli M, et al. Low-volume plus ascorbic acid vs high-volume plus simethicone bowel preparation before colonoscopy. World J Gastroenterol. 2011;17:4689–4695.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Schreiber S, Panes J, Louis E, et al. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol. 2012;12:108.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–549.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Eun Soo Kim
    • 1
  • Kyeong Ok Kim
    • 2
  • Byung Ik Jang
    • 2
  • Eun Young Kim
    • 3
  • Yoo Jin Lee
    • 4
  • Hyun Seok Lee
    • 1
  • Seong Woo Jeon
    • 1
  • Hyun Jin Kim
    • 5
  • Sung Kook Kim
    • 1
    Email author
  • On behalf of Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD)
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineKyungpook National University School of MedicineDaeguKorea
  2. 2.Division of Gastroenterology and Hepatology, Department of Internal MedicineYeungnam University College of MedicineDaeguKorea
  3. 3.Division of Gastroenterology and Hepatology, Department of Internal MedicineCatholic University of Daegu School of MedicineDaeguKorea
  4. 4.Division of Gastroenterology, Department of Internal MedicineKeimyung University School of MedicineDaeguKorea
  5. 5.Division of Gastroenterology, Department of Internal MedicineGyeongsang National University School of MedicineChangwonKorea

Personalised recommendations